

**CDK 4/6 Inhibitors:
Nuance or Difference**

Thursday, April 22, 2021
virtual event (6.00-8.00 pm)



„SCIENCE
FROM THE HEART
OF EUROPE“



Program

- 6.00 pm Welcome**
Michael Gnant
President of ABCSG, Comprehensive Cancer Center Vienna
- 6.10 pm CDKs, Cyclins and CKIs: Roles beyond cell cycle regulation**
Martin Filipits
Head of abcsG.research, Institute of Cancer Research, Medical University of Vienna
- 6.30 pm CDK4/6 Inhibitors: Insights on the development journey from molecules to clinical outcomes**
Giordano Caponigro
Executive Director OTR – Oncology NIBR, Novartis Institutes for BioMedical Research
- 6.50 pm Wrap up — short Q/A**
- 7.00 pm Targeting CDK 4 and 6: What we have learned. An overview of recently published data.**
Gabriel Rinnerthaler
ABCSG, Department of Internal Medicine III, University Hospital Salzburg
- 7.20 pm Overview on actual and planned clinical trials**
Egle Budiene
Region Europe Medical Director Breast Cancer, Novartis
- 7.30 pm Discussion**
Michael Gnant
President of ABCSG, Comprehensive Cancer Center Vienna
Christian Singer
ABCSG, Head of Breast Health Center, Comprehensive Cancer Center Vienna
and all speakers

Michael Gnant

Michael Gnant is Full Professor of Surgery at the Medical University of Vienna. Gnant graduated in medicine in Vienna, and subsequently specialized in Surgery and Surgical Oncology. He also worked as Visiting Scientist at the National Cancer Institute, National Institutes of Health, Bethesda, USA. He is the author of more than 460 original peer-reviewed papers with an impact factor of 3,600 and an h-index of 69. He is the recipient of multiple national and international awards, and a corresponding member of the Austrian Academy of Sciences. Gnant is involved in many scientific societies including ASCO, AACR, ACS, Breast International Group (BIG), EORTC, ESSO, EUSOMA and UICC. Gnant is also Editor-in-Chief (Breast Care), editorial board member and reviewer for many top-tier peer-reviewed journals including The Lancet, The New England Journal of Medicine, and Journal of Clinical Oncology. Since 2015, he hosts and co-chairs the St.Gallen Breast Cancer Conference in Vienna.

Christian F. Singer

Christian F. Singer is Professor of Clinical-Translational Gynecological Oncology, Head of Center for Familial Breast and Ovarian Cancer, and Head of Vienna Center for Breast Health, Medical University of Vienna, Austria. He is a board-certified gynaecologist and professor at the Medical University of Vienna. After graduation from Innsbruck University Medical School, he successfully completed postdoctoral fellowships at the renowned Georgetown University (USA) and at the University of Leuven (Belgium). In addition, he graduated from Harvard University (USA) where he received a "Master of Public Health" degree. Singer now works and teaches at the Medical University of Vienna, where he has specialized in the treatment of breast cancer and the alleviation of climacteric symptoms. He was appointed Full Professor of Clinical-Translational Gynecological Oncology in 2011 and directs the certified Center for Breast Health at the Department of OB/GYN at Medical University of Vienna. He has published numerous scientific articles and book chapters about breast cancer and climacteric symptoms and has received several national and international awards for his research.

Martin Filipits

Martin Filipits obtained his PhD in Biochemistry at the Institute of Biochemistry and Molecular Cell Biology, University of Vienna, in 1993 and worked there as a postdoc until he joined the Department of Internal Medicine I, Division of Oncology, Vienna General Hospital as a scientist. After a year abroad, working as guest scientist at the Cancer Research Laboratories, Queen's University in Kingston, Canada, he returned to his former institute in Vienna – from 2001 on as an Assistant Professor. From then on, he strongly specialized in the field of Oncology. He habilitated in Applied and Experimental Oncology in 2002 and since 2005, he is Associate Professor at the Institute of Cancer Research, Department of Medicine I, at the Comprehensive Cancer Center of the Medical University of Vienna. Martin Filipits is the recipient of multiple awards and is corresponding member of several important scientific societies, committees, study groups and scientific advisory boards. He is the author of more than 130 original peer-reviewed papers with an impact factor of >960 and an h-index of 46.

Gabriel Rinnerthaler

Gabriel Rinnerthaler graduated in Medicine at the Medical University Graz and specialized in the field of Medical Oncology and Hematology at the Department of Internal Medicine III, Paracelsus Medical University Salzburg. There he acts as managing senior physician since 2020. Already since 2007, Gabriel Rinnerthaler participates in translational and clinical research project and acts as an investigator in national and international I-IV phase trials. Lately, he designed study and protocol of the multicenter phase-II-trial ABCSG 52 / ATHENE to investigate Atezolizumab in combination with dual HER2 blockade plus doxorubicin as neoadjuvant therapy for HER2-positive early breast cancer. Furthermore, he is member of the steering committee of the multicenter pro- and retrospective AGMT MBC registry for metastatic breast cancer patients in Austria and member of numerous of societies in the field of Internal Medicine and Oncology in Austria and Europe. Gabriel Rinnerthaler obtained his *venia docendi* for Internal Medicine at the Paracelsus Medical University Salzburg in February 2021, his habilitation treatise discusses “Tissue based biomarkers predicting treatment response in metastatic breast cancer patients”.

Egle Budiene

Egle Budiene is Region Europe Medical Director Breast Cancer at Novartis and has profound expertise in medical affairs activities and drug life cycle management within oncology, but also in vaccines, respiratory and dermatology. She is a medical doctor and trained anaesthesiologist and holds an MBA in International Marketing and Trade. Egle Budiene joined Novartis in 2014 and subsequently specialized as Medical Advisor and Medical Affairs Manager in the field of melanoma therapy. Since 2019 she is Region Europe Breast Cancer Medical Director, Oncology Region Europe and leads the Regional alpelisib clinical trial program, including PASS and decentralized clinical trial pilot in BC. Her professional experience includes evidence generation, medical input for clinical development plans, market access, stakeholder engagement, medical governance and medical information management.

Giordano Caponigro

Giordano Caponigro is Executive Director of the Oncology Translational Research Unit at Novartis Institutes for Biomedical Research in Cambridge. He holds a PhD in Cellular Biology, which he obtained at the University of Arizona, Tucson Arizona. Giordano Caponigro works at the Novartis Institutes of Biomedical Research in Cambridge since over 17 years and has profound experience in Oncology, especially in the field of translational research and drug development. He authored and co-authored numerous peer-reviewed scientific publications in top notch journals.